Vertex Pharmaceuticals Stock News

The top five biotech stocks today have several commonalities. Among them are strong ratings.

Which group of individuals is in the best position to spot early warning signs of economic trouble? There's a good case to be made for corporate chief financial officers (CFOs).

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received the full dose of the inve...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a recession. That's a big concern for the market these days as consumers have been keeping discretionary spending to a minimum as high costs have created many affordability issues.

The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax cond...

Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector.

Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock is among top biotechs to watch.